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Background: To elucidate gene expression associated with copy number changes, we performed a genome-wide
copy number and expression microarray analysis of 25 pairs of gastric tissues.
Methods: We applied laser capture microdissection (LCM) to obtain samples for microarray experiments and
profiled DNA copy number and gene expression using 244K CGH Microarray and Human Exon 1.0 ST Microarray.
Results: Obviously, gain at 8q was detected at the highest frequency (70%) and 20q at the second (63%). We also
identified molecular genetic divergences for different TNM-stages or histological subtypes of gastric cancers.
Interestingly, the C20orf11 amplification and gain at 20q13.33 almost separated moderately differentiated (MD)
gastric cancers from poorly differentiated (PD) type. A set of 163 genes showing the correlations between gene
copy number and expression was selected and the identified genes were able to discriminate matched adjacent
noncancerous samples from gastric cancer samples in an unsupervised two-way hierarchical clustering. Quantitative
RT-PCR analysis for 4 genes (C20orf11, XPO5, PUF60, and PLOD3) of the 163 genes validated the microarray results.
Notably, some candidate genes (MCM4 and YWHAZ) and its adjacent genes such as PRKDC, UBE2V2, ANKRD46,
ZNF706, and GRHL2, were concordantly deregulated by genomic aberrations.
Conclusions: Taken together, our results reveal diverse chromosomal region alterations for different TNM-stages or
histological subtypes of gastric cancers, which is helpful in researching clinicopathological classification, and
highlight several interesting genes as potential biomarkers for gastric cancer.
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Despite its steady declining trend worldwide, gastric cancer
is still the second most common cause of cancer related
deaths with 700,000 cases annually [1]. Due to no symp-
toms at the early stage of gastric cancer, it is often detected
at the advanced stage and the prognosis for treatment at
that time is poor [2]. Therapeutic interventions to treat
such late stage carcinomas are usually restricted to non-
curative gastrectomy, lymphadenectomy and postoperative
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reproduction in any medium, provided the orgastric cancer patients barely reach below 30% in most
countries [3]. It is of great clinical importance to identify
new biomarkers for early diagnosis, targeted treatment and
prognosis evaluation in gastric cancer.
Gastric cancers can be divided into two main histo-
logical subtypes, differentiated and poorly differentiated
(PD) adenocarcinomas. Differentiated adenocarcinoma is
defined by tubular or glandular formation with cancer
cells similar to the intestinal metaplasia, whereas the PD
type is characterized by disruption of tubular formation
due to reduction or loss of cell-cell interaction [4]. The
PD adenocarcinomas occur in relatively young indivi-
duals and often metastasize to the peritoneum or lymph
nodes, resulting in a poor prognosis [5]. Despite the
aggressive nature of PD gastric cancer, little is known
about the precise mechanisms of carcinogenesis or pro-
gression and specific therapeutic targets.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions accumulating during the long process of carcino-
genesis are responsible for the initiation and progression
of cancers [6]. DNA copy number variations (CNVs) are
important influential factors for altered gene expression
levels in cancer. Recently, integration of genome-wide
array-based comparative genomic hybridization (aCGH)
and gene expression microarray data has provided a new
insight about the molecular mechanisms underlying
gene expression alterations [7-10]. In previous studies,
various microarrays (cDNA, BAC or PAC clone, oligo)
were applied to investigate CNVs of gastric cancer. Due
to the limit of resolution, sample size and preparation
method, the impact of CNVs on gene expression
remains poorly understood.
In this study, we performed genome-wide DNA copy
number and gene expression profiling of 25 pairs of gas-
tric tissues to identify genes that show correlated pat-
terns of variations. Our study applied laser captureFigure 1 DNA copy number change profiles in the 27 pairs of gastric
The CNVs frequency of the whole genome was analyzed by aCGH. Gains wmicrodissection (LCM) to reduce the contamination of
cancer cells by non-cancer cells. We also analyzed aber-
ration patterns of different gastric cancer histopathology
subtypes to highlight molecular markers with potential
clinical significance.
Results
DNA copy number variations in gastric cancer
The 27 pairs of gastric samples were analyzed by aCGH
as shown in Additional file 1: Table S3. The CNVs of all
the chromosomes were displayed in Figure 1A. The fre-
quency of CNVs was detected across the entire genome
(Figure 1B). Noticeably, chromosomes 8, 20, and 7 con-
tained more genes undergoing frequent copy number
amplifications, whereas the high frequent copy number
deletions were observed on chromosomes 6, 3, 4, and
18. CNVs frequently detected in gastric cancer were
summarized in Table 1. The gained regions detected in
at least 25% of the samples were located at 8p11-q24,samples. (A) Summary of chromosomal aberrations was shown. (B)
ere marked in red and losses in green.
Table 1 Chromosomal copy number gains and losses
detected in at least 25% of gastric cancer samples
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13q13-q14, 6p21, 6p12, 7p15, 13q12, 20p13, 1q42, and
7p22 in decreasing order of frequency (Table 1). Regions
of loss detected in at least 25% of the samples were
located at 4q34, 6p25, 18q12, 18q22, and 3p14 in de-
creasing order of frequency (Table 1). Minimal common
regions of these copy number aberrations were shown in
Table 2, including the size, frequency, possible target
genes, and chromosomal position of the alteration in
base pairs. Possible target genes were selected with at
least two-fold copy number associated changes in gene
expression levels.
Gastric cancers of different TNM-stages and histological
subtypes show diverse copy number aberrations
We compared DNA copy number aberration profiles of
different gastric cancer TNM-stages and histological sub-
types, and found 11 noteworthy regions that displayed dif-
ferences in copy number changes between PD (n=10) and
MD (n=11) (Figure 2A). Of these, 2 regions (3p14.1 and
19p13.12) were more commonly altered in PD cancers
compared with the MD type. Seven regions (1p36.33,
6p24.3, 7p21.1, 7p15.2, 20p12.1, 20q12, and 20q13.2) were
more commonly altered in the MD type, and 2 regions
(20p11.21 and 20q13.33) were significantly altered in both
groups. We observed that chromosome 20 showed moredifferent regions in copy number variations between PD
and MD type. Moreover, we found that the MD type could
be classified by amplification of C20orf11 at 20q13.33
(two-sample t-test, P<0.05) (Figure 3).
Besides, we also performed the comparisons in copy
number changes for T1-2 (n = 11) versus T3-4 (n = 13)
as well as N0 (n = 14) versus N1-3 (n = 11). We found
that the frequencies of loss at 4p16.1, 4p14, 4q13.2,
5q21.1, 9q21.13, 9q22.31, 10q22.1, 12q15, 14q24.2,
22q11.21, and 22q12.2 were significantly higher in T3-4
stages than in T1-2 stages, while one region (10q22.1)
showed more gains in T1-2 stages. One region, 6q15
had both significant gains and losses in T3-4 stages com-
pared to T1-2 stages (Figure 2B). DNA copy number
variation profiling of N0 and N1-3 stages also revealed
18 significantly altered genomic regions (1q32.2,
1q42.12, 2q14.1, 2q14.2, 2q35, 3p25.3, 3q26.2, 5q33.3,
6q16.3, 6q22.33, 7q11.22, 9p23, 9q33.2, 11q23.3, 11q25,
14q11.2, 14q32.11, and 15q24.1) which showed more
aberrations in N1-3 stages compared with N0 stage
(Figure 2C).
Copy number associated gene expression changes
We found that 163 individual genes showed at least a
1.3-fold copy number associated alteration in their ex-
pression (range 1.3 – 9.8, median 1.4) (Additional file 2:
Table S4). Of these, there was no gene located in the re-
current regions of copy number loss. The gene showing
the highest correlation was PI3 (FC = 9.8). PI3 (peptidase
inhibitor 3, skin-derived (SKALP)) gene, amplified in the
20q12-q13.2 region, displayed the strongest copy num-
ber amplification correlated overexpression in gastric
cancer. Generally, the highest gene expression fold
changes between tumor samples with and without copy
number amplifications were detected at the 6p region
since out of the 20 genes showing >1.7-fold copy
number associated changes in their expression, 11
(55.0%) were located in the 6p region (Additional file 2:
Table S4). Altogether those included genes showing sig-
nificant enrichment (Score > 1.3) in basic functions such
as DNA replication (TOP1, MCM4, POLB, and MCM3).
An unsupervised two-way (genes and samples) hierarch-
ical clustering of 25 pairs of tissue samples based on
these genes revealed two distinct clusters separating
matched adjacent noncancerous samples from gastric
cancer samples (Additional file 3: Figure S2). We per-
formed qRT-PCR for 4 genes (C20orf11, XPO5, PUF60,
and PLOD3) from the 163 genes. These genes showed
statistically significant copy number associated gene
expression alterations, suggesting that our microarray
data are reliable (Figure 4).
To further highlight these 163 genes obtained by gene ex-
pression fold change, Pearson correlation coefficients be-
tween copy number log2ratios and expression log2ratios for
Table 2 Minimal common regions of recurrent (≥ 25%) copy number amplification and deletion
Aberration Position (Mb) Size (Mb) Frequency, n = 27 (%) Possible target genes
+1q42.3 233.85-233.86 0.02 7 (26%) -
+6p21.1 43.41-44.34 0.94 8 (30%) MRPL14, POLR1C, HSP90AB1, XPO5, MRPS18A
+6p12.2 52.22-52.43 0.20 7 (26%) MCM3
+6p12.2-p12.1 52.44-52.98 0.54 7 (26%) TMEM14A
+7p21.1 16.68-17.28 0.60 8 (30%) BZW2
+7p12.2 50.62-50.67 0.05 7 (26%) -
+7p12.1-p11.1 53.84-57.47 3.63 9 (33%) MRPS17, CCT6A
+7q11.21-q11.23 63.35-73.62 10.27 9 (33%) CLDN4, EIF4H, SBDS, WBSCR22
+7q11.23 73.63-75.81 2.18 9 (33%) MDH2
+7q21.12-q21.13 87.54-90.07 2.52 7 (26%) SRI, CLDN12
+7q21.2 91.91-92.53 0.62 7 (26%) -
+7q21.3-q22.1 97.67-100.86 3.19 9 (33%) PLOD3, POP7, ARPC1A, COPS6, BUD31
+8p11.21-q11.1 42.35-47.79 5.44 8 (30%) VDAC3
+8q11.1-q24.3 47.86-146.27 98.41 19 (70%) *
+13q13.3 39.19-39.28 0.10 7 (26%) -
+13q14.11 39.81-40.58 0.77 8 (30%) -
+20p13 0.19-0.71 0.52 7 (26%) -
+20p12.1-p11.23 17.53-17.98 0.46 8 (30%) -
+20p11.21 24.84-25.35 0.51 10 (37%) -
+20q11.21-q12 29.40-40.53 11.12 14 (52%) TPX2, RPN2, POFUT1, CHMP4B, TOP1
+20q12-q13.2 40.54-52.12 11.57 11 (41%) CTSA, SLPI, MYBL2, PI3, YWHAB, TOMM34, B4GALT5, PIGT, C20orf111
+20q13.33 57.96-62.15 4.19 10 (37%) PSMA7, C20orf11
−3p14.2 60.42-60.48 0.06 7 (26%) -
−6p25.3 1.86-2.02 0.16 9 (33%) -
−18q22.1 60.04-60.07 0.02 7 (26%) -
*, possible target genes at 8q11.1-q24.3 included GRINA, MYC, PRKDC, LAPTM4B, SQLE, FAM91A1, GGH, PPM2C, RAD21, MCM4, LACTB2, ENY2, SIAHBP1, UBE2V2,
YWHAZ, RAB2, SLC25A32, MAL2, CHCHD7, LYPLA1, ATP6V1C1, TPD52, EIF3S6, INTS8, HRSP12, and ZFAND1. +, copy number amplification. −, copy number deletion
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133 (81.6%) showed statistically significant correlations be-
tween DNA copy number and gene expression, with a me-
dian correlation coefficient of 0.69 (range 0.40-0.96)
(Additional file 2: Table S4). Correlations between copy
number change and expression level in two representative
genes (XPO5 and MCM4) were exhibited in Additional file
4: Figure S3.
Candidate genes at chromosome 8q
Obviously, gain at 8q11-q24 was detected at the highest
frequency (70%) (Table 1). Furthermore, we found that
32 genes selected from genes located at 8q11-q24 via a
two-sample t-test (P < 0.0001) from 50 gastric tissues
were overexpression along with copy number gain (ex-
cluding GRINA, lack of aCGH data) and revealed a dis-
tinct clustering of the genes overexpressed in gastric
cancer samples and underexpressed in matched adjacent
noncancerous samples (Figure 5).
We noticed that expression of candidate genes
located adjacent to MCM4 at 8q11.21, includingPRKDC and UBE2V2, and YWHAZ at 8q22.3 includ-
ing ANKRD46, ZNF706, and GRHL2, showed the
same trends as that of MCM4 and YWHAZ, respect-
ively (Figure 6). In addition, these genes were concor-
dantly up-regulated in the samples of gastric cancer
with amplification at 8q11.21 (Figure 6A, c) or 8q22.3
(Figure 6B, c).
Discussion
In this study, we performed a genome-wide analysis of
DNA copy number and gene expression changes in gas-
tric cancer to identify genes whose expression are
deregulated due to altered copy number and to find
potential molecular markers with biological roles in
gastric carcinogenesis. Using oligo-based aCGH, gene ex-
pression microarrays as well as bioinformatics methods,
we acquired genes that were differentially expressed in
association with copy number variations. Diverse copy
number profiles of different gastric cancer TNM-stages
(T1-2 vs. T3-4 and N0 vs. N1-3) and histological
subtypes (PD vs. MD) were also shown, implicating the
Figure 2 Copy number aberration profiles of different gastric cancer subtypes revealed significantly altered genomic regions. The
clinical sample group comparisons were performed for PD (n = 10) vs. MD (n = 11) (A), T1-2 (n = 11) vs. T3-4 (n = 13) (B), and N0 (n = 14) vs. N1-3
(n = 11) (C).
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Figure 3 The mRNA level of C20orf11 in normal gastric tissues (N) and gastric cancer tissues (T). Relative expression was from expression
microarray and qRT-PCR. Data were presented as Box and Whisker plots with *P< 0.05, **P< 0.01, and ***P< 0.001. ΔCt-values denoted up-
regulated expression in T as compared with N. MD-amp, the MD gastric cancer samples with amplification at C20orf11; MD-normal, the MD
gastric cancer samples without CNVs at C20orf11.
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in diagnostics and in selecting therapy modalities for dif-
ferent gastric cancer subtypes.
On the whole, we identified recurrent copy number
gains in 15 chromosomal regions and losses in 5 chromo-
somal regions which were consistent with the previously
published studies [11-20]. Noticeably, gain at 8p11-q24
was detected at the highest frequency (70%) and 20q11-
q13 at the second (63%). Taken together, we speculated
that the identified CNVs, especially gain at 8q11-q24 as
well as including candidate genes (SULF1, PRKDC,
LAPTM4B, GRINA, FAM91A1, GPR172A, PPM2C,
MCM4, ENY2, RAD21, SIAHBP1, SLC25A32, PTDSS1,
ATP6V1C1, INTS8, and so on) (Figure 5), may play an
important biological role in the pathogenesis of gastric
cancer. Indeed, a detailed genomic analysis of chromo-
some 8q has been performed on gastroesophageal junc-
tion (GEJ) adenocarcinomas and this study revealed
other genes (ANXA13, MTSS1, FAM84B, C8orf17, and
PTK2) except MYC involved in the 8q amplification and
the pathology of GEJ adenocarcinomas [19].
In addition, it was the first time for this findings that
expression of MCM4, PRKDC, and UBE2V2 at 8q11.21,
or YWHAZ, ANKRD46, ZNF706, and GRHL2 at 8q22.3
was co-regulation and was concordantly up-regulated in
the samples of gastric cancer with amplification at
8q11.21 or 8q22.3. MCM4 is one of the highly conserved
mini-chromosome maintenance proteins (MCM) that
are essential for the initiation of eukaryotic genome repli-
cation and is highly expressed in esophageal cancer and
cervical squamous cell carcinoma [21,22]. Although
negative DNA-PKcs (DNA-dependent protein kinase
catalytic subunit, also known as PRKDC) expression has
been reported to be found in about 20% (114/564) ofhuman gastric cancers and be associated with gastric
cancer progression and poor patient survival, especially
for stage I gastric cancer patients [23,24], it is positively
expressed in 36.8% (82/223) of nasopharyngeal carcin-
oma tissues and is in association with low 5-year overall
survival rate [25]. In our study, PRKDC was up-regulated
(at least a two-fold change in the gene expression level)
in 64% (16/25) of gastric cancer samples. Details of its
expression in human cancer are controversial, so further
studies will be needed to clarify the mechanism for
PRKDC. It has been reported that hMMS2 (methyl
methanesulfonate sensitive 2, S. cerevisiae, homolog of,
also known as UBE2V2) serves a redundant role in
human PCNA polyubiquitination [26]. Therefore, we
speculated that these overexpressed genes located at
8q11.21 may concordantly play an important role in the
pathogenesis of gastric cancer. Indeed, a recent study has
also shown that genes located adjacent to EGFR at 7p11
or SMAD4 at 18q21 were in close association with one
another and may play a role in the pathogenesis of
advanced gastric carcinoma [9]. Although YWHAZ at
8q22.3 has been considered as a potent antiapoptotic
gene [27], we cannot exclude the possibility that other
candidate genes may also be present in the region.
Gastric cancers of different TNM-stages or histo-
logical subtypes display diverse copy number aberra-
tions. In our study, the MD type tended to be
distinguished by gains of C20orf11 at 20q13.33. It has
been reported to the higher frequency of 20q amplifi-
cations in intestinal gastric cancer [20]. A study has
also previously shown that copy number gains at 20q
are significantly frequent in cell lines derived from
tumors of the well-differentiated type [28]. Genetic di-
vergence was also revealed between the T1-2 and T3-4
Figure 4 Correlation between copy number ratios and expression ratios in representative genes was validated by qRT-PCR. Each dot
indicates an individual sample. The X axis displays copy number log ratios and the Y axis shows gene expression log ratios from microarray (A) or
qRT-PCR (B). FDR, false discovery rate.
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10q22.1, and 14q24.2 showed copy number gains in T1-2
and copy number losses in the T3-4 stages. Two regions,
9q22.31 and 22q12.2 both had significant losses in the T3-
4 stages. In addition, 9p23 and 15q24.1 were found to be
more common gains in N0 and losses in N1-3 type gastriccancers. It was the first time to in detail give DNA copy
number profiles of different gastric cancer TNM-stages
and histological subtypes. Taken together, these studies
provided a new insight about researching pathological
classification which is helpful to estimate prognosis or per-
sonalized therapy for different gastric cancer subtypes.
Figure 5 Correlation between copy number gains and overexpression of 31 genes at 8q11.1-q24.3. The genes were arranged in
chromosomal order (p!q). An unsupervised hierarchical clustering of 50 gastric tissues with 32 genes overexpressed in gastric cancer samples
(T) and underexpressed in matched adjacent noncancerous samples (N) revealed two distinct clusters (on the right). The genes included MCM4,
PRKDC, UBE2V2, LYPLA1, LYN, CHCHD7, RAB2, GGH, SULF1, LACTB2, SLC10A5, PTDSS1, INTS8, LAPTM4B, PPM2C, RPL30, ATP6V1C1, SLC25A32, YWHAZ,
ZNF706, CTHRC1, ENY2, RAD21, EIF3S3, MAL2, FAM91A1, FBXO32, SQLE, MYC, GPR172A, SIAHBP1, and GRINA (lack of aCGH data).
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pression was deregulated in association with copy number
variation. Combining the other recent studies, our study
revealed 12 overlapping genes: POLR1C (6p21.1), LANCL2
(7p12.1-p11.1), CCT6A (7p12.1-p11.1), MRPS17 (7p12.1-
p11.1), SMURF1 (7q21.3-q22.1), COPS6 (7q21.3-q22.1),
SQLE (8q11.1-q24.3), RRBP1 (20p12.1-p11.23), SNX5
(20p12.1-p11.23), ID1 (20q11.21-q12), PI3 (20q12-q13.2),
and PARD6B (20q12-q13.2) in at least one of the previ-
ously published studies [7-10]. Novel genes included
SIAHBP1, ATP6V1C1, SLC25A32, ZFAND1, MCM4,
XPO5, PLOD3, PSMA7, EIF3S6, TPD52, NSMCE2,
MRPS18A, STK3, and MAD2L1BP with no previousFigure 6 Concordant deregulation of candidate genes at 8q11.21 and
8q11.21 (A) and YWHAZ at 8q22.3 (B) shows the same trends as that of MC
neighboring candidate genes at 8q11.21 and 8q22.3; (b) Pearson’s correlati
Expression log ratio of the individual gene in each sample. Gain (−)/Gain (+
Amp (+) was referred to samples with amplification at 8q11.21 or 8q22.3.gastric cancer associated reports. Moreover, 17 of the
identified genes (CLDN4, SRI, MYC, PRKDC, SLPI,
LAPTM4B, MYBL2, YWHAB, YWHAZ, MCM3, SER-
PINE1, SLC29A1, ID1, CDK6, EIF2C2, PTK2, and GSTA1)
have previously been implicated in gastric cancer, and six
of the genes (MYC, SBDS, CHCHD7, TOP1, COX6C, and
CDK6) are included in the Cancer Gene Census [29].
Based on previous studies [30-32], we applied 1.3-fold
cut-off for selecting genes with alteration in their expres-
sion. Moreover, we performed Pearson correlation ana-
lysis between copy number and expression for these 163
correlated genes to further highlight them. Out of the
genes analyzed, 133 (81.6%) showed statistically8q22.3. Expression of candidate genes located adjacent to MCM4 at
M4 and YWHAZ, respectively. (a) Schematic genome structures of
on coefficients of expression log ratios among candidate genes; (c)
) was referred to samples with or without gain at 8q11.21 or 8q22.3;
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gene expression (Additional file 2: Table S4). According
to gene expression fold changes (FC), PI3 showed the
highest correlation (FC = 9.8). But its Pearson correlation
coefficient was 0.18. So the contradiction revealed that
the method applying gene expression fold changes[10]
to obtain correlated genes was not a strong manner.
To validate the microarray results, four genes
(C20orf11, XPO5, PUF60, and PLOD3) were selected for
qRT-PCR. The C20orf11 gene displayed copy number
correlated overexpression in MD type gastric cancer
according to the microarray and qRT-PCR analysis (Fig-
ure 3). To our knowledge, no previous report regarding
the possible tumor association of C20orf11 has been
published. Twa1 (two hybrid-associated protein 1 with
RanBPM), also known as C20orf11, was well conserved
through evolution and was localized within the nucleus.
Interestingly, Twa1 was found to possess the LisH-
CTLH motif which is detected in proteins involved in
microtubule dynamics, cell migration, nucleokinesis and
chromosome segregation [33]. A study indicated that
both Twa1 and hMuskelin comprise a protein complex
with RanBPM [34]. It has been shown that XPO5
(Exportin-5) is key to miRNA biogenesis and may help
coordinate nuclear and cytoplasmic processing steps
[35]. Exportin-5 controls Dicer1 expression post-
transcriptionally and alterations in miRNA expression
can strongly influence cellular physiology [36]. A recent
study has shown that the XPO5 genetic defect traps pre-
miRNAs in the nucleus of cancer cells, reduces miRNA
processing, and diminishes miRNA-target inhibition. Im-
portantly, the restoration of XPO5 functions reverses the
impaired export of pre-miRNAs and has tumor-
suppressor features in a subset of cancers with microsat-
ellite instability (MSI+) [37]. In our study, XPO5 exhib-
ited copy number associated overexpression in gastric
cancer. PUF60 (poly-U binding splicing factor 60KDa,
also known as FIR and SIAHBP1) has been reported to
regulate c-myc transcription through the general tran-
scription factor TFIIH [38]. A study has displayed that
the deficiency of LH3 (lysyl hydroxylase 3, also known as
PLOD3) glycosyltransferase activities, especially in the
extracellular space, causes growth arrest [39]. Due to the
limitation in the number of samples, correlations be-
tween copy number alteration and gene expression level
from qRT-PCR were almost lower than the microarray
data. In all, qRT-PCR analysis validated the microarray
results and highlighted some interesting genes as poten-
tial target genes.Conclusions
In conclusion, the integrated analysis of gene copy num-
ber and expression pointed out several interesting genesas potential biomarkers for gastric cancer although
further studies need to be performed. We also identified
diverse chromosomal regions involved in different
TNM-stages or histological subtypes of gastric cancer.
Taken together, these results were helpful in clinical
stages and early diagnosis or treatment of gastric cancer.
Methods
Samples and laser capture microdissection
A total of 27 gastric cancer tissues and matched adjacent
noncancerous tissues were obtained from the tissue bank
of Shanghai Biochip Center (SBC), which were collected
immediately after surgical resection and snap-frozen in li-
quid nitrogen, then stored in the tissue bank of SBC till
later use. Informed consent was obtained from each par-
ticipating patient. Ethics approval for this study was
granted by the Human Research Ethics Committee of
Shanghai Jiaotong University School of Medicine. All tis-
sue samples were double examined with hematoxylin &
eosin staining method by two individual pathologists. The
clinical and pathological information on the patients was
summarized in Additional file 5: Table S1. All tumors
were reviewed for invasion (T), lymph node status (N),
and metastasis (M). Distant metastasis (M1) was seen in 6
cancer samples. Our cancer tissue samples consisted of
two differentiation subtypes: PD (n= 12) and moderately
differentiated (MD, n= 11) besides moderately-poorly dif-
ferentiated (M-PD, n= 4) type. All gastric cancer samples
were adenocarcinomas and two of the tumor samples
showed partial signet-ring cell carcinomas.
Sections of 8 μm thickness were produced on a
Microm HM 550 microtome (Microm, Walldorf, Ger-
many) and mounted on room-temperature Silane Prep
slides (MMI, Glattbrugg, Switzerland). After staining
with HistoGene LCM Frozen Section Cresyl Violet Stain-
ing Kit (Ambion, Austin, TX), microdissection was per-
formed using MMI CellCut LCM system (MMI), under
100× magnification. Tumor or non-malignant cells were
captured from cancerous or adjacent noncancerous tis-
sues using LCM macro caps (MMI), respectively, and the
number of about 5,000 cells was collected within 40 min-
utes after cryo-section for each slide. Additional file 6:
Figure S1 showed efficiency of cell capturing.
Genomic DNA and total RNA preparation
Following tissue collection, the caps with the captured
cells were incubated in 50 μl buffer ATL of QIAamp
DNA Micro Kit (Qiagen, Hilden, Germany), stored in
4°C for later genomic DNA isolation, or incubated in
100 μl of lysis solution of RNAqueous-Micro Kit
(Ambion) at 42°C for 30 minutes, then frozen at −80°C
till later total RNA isolation. Genomic DNA (gDNA)
and total RNA were extracted using proper reagents
according to the manufacturer’s protocols. The quality
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esis, and DNA concentration was measured using
Nanodrop ND-1000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE). Total RNA integrity,
purity and concentration were determined with Agi-
lent’s 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA) (data not shown). Only RNAs with RNA in-
tegrity number (RIN) >7.0 were applied in later micro-
array experiments.
Oligo-based aCGH
Genomic imbalances of 27 pairs of gastric samples were
analyzed by aCGH using 244 K CGH Microarrays con-
taining 244,000 probes with 8.9 KB overall median probe
spacing (7.4 KB in Refseq genes) (Agilent Technologies).
The gDNA (500 ng) was digested using Alu I and Rsa I
restriction enzymes (Promega, Madison, WI), and la-
beled with either Cy5- or Cy3-dUTP fluorescent dyes for
cancerous and adjacent noncancerous samples, respect-
ively, using Agilent Genomic DNA Labeling Kit Plus
(Agilent Technologies). Labeled DNA products were
purified with Microcon YM-30 filtration devices (Milli-
pore, Bedford, MA), and DNA yield and dye incorpor-
ation were determined. Then equal amount of the
labeled sample pairs were mixed and hybridized on
CGH microarrays by using the SureHyb chambers, for
40 hours at 60°C. After washing, the microarray slides
were scanned immediately using an Agilent microarray
scanner, and raw data were extracted using Feature Ex-
traction Software version 9.5.3 at the default CGH par-
ameter settings (Agilent Technologies).
Putative CNV intervals in each sample were identified
using Agilent CGH Analytics software ver. 4.0.76. Cy5/
Cy3 ratios were converted into log2-transformed values.
Centralization and fuzzy zero corrections were applied
to the microarray. The ADM-2 algorithm at threshold 4
was used to identify the CNVs in individual samples and
to determine aberration frequencies in gastric cancer
samples. In addition, the following aberration filters were
employed: minimum number of probes in region = 2,
minimum absolute average log2 ratio for region = 0.5,
maximum number of aberration regions = 10,000. The
log2 ratio of 0.5 corresponds to a 1.4-fold variation in
the DNA copy number. Genes in CNVs were annotated
by SCAN [40]. Chromosome Y was removed from the
analysis. Original copy number data have been submit-
ted to NCBI's Gene Expression Omnibus (GEO) [41]
and are accessible through GEO Series accession num-
ber [GEO: GSE33428] (http://www.ncbi.nlm. nih.gov/
geo/query/acc.cgi/acc =GSE33428). Minimal common
regions of recurrent variations in the 27 samples were
analyzed, including the size and chromosomal position
of the aberration. An alteration was defined as recurrent,
if it was present in at least 25% of the samples [10].To compare DNA copy number aberrations in differ-
ent gastric cancer TNM-stages or histological subtypes,
we used a Fisher’s exact test based on the 3 × 2 table in
each region, with the rows representing different gastric
cancer histopathology subtypes and the columns repre-
senting number of samples with copy number gain, nor-
mal copy number or copy number loss in that region
[42]. Statistical significance was recognized with P-
value < 0.05. Due to the gender differences between the
arrays that could cause bias in the analysis, chromo-
somes X and Y were excluded from the calculation. Two
tumor samples which showed partial signet-ring cell car-
cinomas were also removed from the analysis. The clin-
ical sample group comparisons were performed for PD
(n = 10) vs. MD (n = 11), T1-2 (n = 11) vs. T3-4 (n = 13)
and N0 (n = 14) vs. N1-3 (n = 11). To ensure meaningful
copy number patterns, at least 25 percent of the samples
had to have classifying gains or losses in at least one of
the compared classes.
Gene expression microarray
Twenty-five pairs of gastric samples were used for gene
expression profiling. Total RNAs were labeled with Affy-
metrix GeneChip Whole Transcript Sense Target Label-
ing and Control Reagents Kit, and hybridized to Human
Exon 1.0 ST microarrays (Affymetrix, Santa Clara, CA).
In brief, one hundred nanograms of starting total RNAs
was used in first round double strand (ds)-cDNA synthe-
sis and cRNA synthesis; 8–10 μg of cRNA could be got
and then used in second round single-strand (ss)-cDNA
synthesis. Ss-cDNA fragmentation and labeling were fin-
ished according to the Whole Transcript Sense Target
Labeling Assay manual (Affymetrix). Five micrograms of
biotin labeled ss-cDNA was used to hybridize the
Human Exon 1.0 ST microarray for 16 hours. Staining
and washing were all processed with Affymetrix’s proto-
cols. The arrays were scanned on the GeneChip Scanner
3000 7 G with GeneChip Operating Software ver. 1.3
(Affymetrix) to generate .CEL intensity files.
Expression Consol software (v 1.0) (Affymetrix) inte-
grated robust multiarray analysis (RMA) algorithm was
applied to extract gene-level expression signal and detec-
tion above background (DABG) P-value for each probe
set of the samples. Probe sets with P <0.05 were consid-
ered as present, and an expression signal cutoff was set
as 3.9, as minimum number of falsely called probes.
Only the genes with signal above cutoff were used in
later analysis. All gene expression data are available at
NCBI via GEO [GEO: GSE33335] (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi/acc =GSE33335).
Integrative analysis of the CGH and expression data
To investigate the correlation between DNA copy num-
ber and gene expression, we only analyzed genes located
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The purpose of this way was to pinpoint gene expression
changes that were associated with alterations in DNA
copy number, and could therefore enlighten some poten-
tial oncogenes, tumor-suppressor genes and stability
genes with functional roles in cancers. Amplifications
and deletions were treated separately in the analysis. The
median expression level of each gene was compared be-
tween cancer samples with and without copy number
amplifications/deletions to assess the effect of copy
number changes on gene expression. Gene expression
fold changes (FC) were calculated by dividing the me-
dian expression of the cancer samples with CNVs by the
median expression of the cancer samples without copy
number alterations [10]. At least 1.3-fold copy number
associated aberration in gene expression was selected.
The functional annotation analysis of selected genes was
performed using the DAVID Database [43,44]. A score
of over 1.3 was considered to be a significant level of en-
richment in the gene set with a minimum gene count
threshold of ≥ 2. The selection of the genes that dis-
played the correlations between copy number and ex-
pression changes would be expected to exhibit a
differential gene expression pattern between normal gas-
tric tissues and gastric tumor tissues [7]. That expect-
ation was realized by hierarchical clustering of 25 pairs
of gastric samples with these genes using the average
linkage method. Visualization was performed in Java
Treeview 1.1.3 software. Pearson correlation coefficients
between DNA copy number aberrations and alterations
in mRNA expression level for each selected gene were
also calculated in SPSS 11.5 software to further highlight
these genes with association between copy number and
expression. The results from the integrated microarray
analysis were compared with four previously published
studies that systematically integrated genome-wide gene
copy number and expression data [7-10].
In addition, we also analyzed genes located in diverse
chromosomal regions of different gastric cancer TNM-
stages or histological subtypes and identified genes with
the correlation between gene copy number and expres-
sion change based on the above method.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
For validation of the microarray data, the qRT-PCR was
performed with SYBR Green assay in ABI 7300 Real Time
PCR System according to the manufacturer’s instructions.
All primers (Additional file 7: Table S2) were designed
using Primer Express 3 (Applied Biosystems, Foster City,
CA). Specificity of primer sets was checked with BLAST.
Forward and reverse primers were mixed and diluted to
5 μM. Two micrograms of total RNAs extracted from 19
pairs of gastric samples was reverse transcribed into cDNAusing First Strand cDNA Synthesis Kits (Fermentas, Glen
Burnie, Maryland) as was suggested by the manufacturer.
Then cDNA was diluted 1:10. The RT-PCR master mix-
tures consisted of: 1 μl primers, 1 μl diluted cDNA, 10 μl
2 × SYBR Green master mix (TOYOBO, Osaka, Japan),
8 μl RNA-free water in a final volume of 20 μl. All assays
were normalized by the ACTB internal control. Thermal
cycling conditions comprised 50°C for 2 min, 95°C for
5 min, followed by 40 cycles of 95°C for 15 s and 60°C for
1 min. All reactions were performed in triplicate. Relative
quantification results were analyzed using the 2-ΔΔCt
method.
Additional files
Additional file 1: Table S3 The 27 pairs of gastric samples were
analyzed by aCGH using Agilent CGH Analytics 4.0.76 software. ADM-2
algorithm with a threshold level of 4 was used to identify CNVs in
individual samples. CNVs, copy number variations.
Additional file 2: Table S4 Copy number associated gene expression
changes. Pearson correlation coefficients between DNA copy number
aberrations and alterations in mRNA expression level for each selected
gene were calculated in SPSS 11.5 software. Gene expression referred to
log2 ratios from gene expression profiling. Normal and Tumor referred to
an average log2 ratio of 25 pairs of gastric samples, respectively. aCGH
log2 ratio referred to an average log2 ratio for only those cases
(Frequency) in which the ratio was over 1.5-fold changed (log2
ratio≥ 0.585 or≤−0.585). firstly, a mean log2 copy number variation ratio
was calculated for all the probes targeting the same gene. Then, the
Pearson’s r was measured between aCGH and gene expression profiling
performed in 25 pairs of gastric samples.
Additional file 3: Figure S2 An unsupervised hierarchical clustering of
50 gastric samples with 163 genes revealed two distinct clusters. Log
ratio scale bar for the Treeview color change was also shown. Suffix “T”
indicates gastric cancer samples; “N” indicates matched adjacent
noncancerous samples.
Additional file 4: Figure S3 Correlation between copy number ratios
and expression ratios in representative genes (XPO5 and MCM4). The X
axis showed 25 gastric samples and the Y axis displayed log ratios of
copy number and gene expression from microarrays.
Additional file 5: Table S1 Clinical and histological data of the 27 pairs
of gastric samples. M, male; F, female; ADC, adenocarcinoma; SRCC,
signet-ring cell carcinoma; T, invasion activity; N, lymph node
colonization; M, metastasis; Dif, differentiation; Hp, helicobacter pylori;
MD, moderately differentiated; PD, poorly differentiated; M-PD,
moderately-poorly differentiated; NA, not available.
Additional file 6: Figure S1 Efficiency of cell capturing. Noncancerous
mucosa (A) before and (B) after dissection of the epithelia. (C) Image of
the epithelium on the cap. Tumor cells in muscle layer (D) before and (E)
after dissection of the tumor cells. (F) Image of the tumor cell on the cap.
Additional file 7: Table S2 All primers were used in the qRT-PCR
validation of gene expression microarray data.
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